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Abstract
Objective: To assess the impact of nonuniform dose distribution within lesions and tumor-involved organs of
patients receiving Zevalin, and to discuss possible implications of equivalent uniform biological effective doses
(EU-BED) on treatment efficacy and toxicity. MATLAB -based software for voxel-based dosimetry was
adopted for this purpose.
Methods: Eleven lesions from seven patients with either indolent or aggressive non-Hodgkin lymphoma were
analyzed, along with four organs with disease. Absorbed doses were estimated by a direct integration of single-
voxel kinetic data from serial tomographic images. After proper corrections, differential BED distributions and
surviving cell fractions were estimated, allowing for the calculation of EU-BED. To quantify dose uniformity in
each target area, a heterogeneity index was defined.
Results: Average doses were below those prescribed by conventional radiotherapy to eradicate lymphoma
lesions. Dose heterogeneity and effect on tumor control varied among lesions, with no apparent relation to
tumor mass. Although radiation doses to involved organs were safe, unexpected liver toxicity occurred in one
patient who presented with a pattern of diffuse infiltration.
Conclusion: Voxel-based dosimetry and radiobiologic modeling can be successfully applied to lesions and
tumor-involved organs, representing a methodological advance over estimation of mean absorbed doses.
However, effects on tumor control and organ toxicity still cannot be easily predicted.
Key words: BED, EUD, ibritumomab-tiuxetan, lymphomas, NHL, radioimmunotherapy, voxel-based dosimetry,
zevalin
Introduction
Internal dosimetry is constantly evolving with the use ofradioimmunotherapy (RIT) for hematological malignan-
cies.1,2 Different dosimetric protocols have been developed
for the two commercially available antilymphoma agents,
131I-tositumomab (Bexxar) and 90Y-ibritumomab-tiuxetan
(Zevalin). Because of the unpredictable biokinetics of 131I-
tositumomab, a pretherapy dosimetric study is mandatory in
RITwith Bexxar (RIT-B) for tailoring the administered activity
to deliver a total body dose of 75 or 65 cGy, according to the
platelet count.3 In contrast, with the radiometal conjugate
Zevalin (RIT-Z), the activity to be administered is based on
patient weight and platelet counts rather than on pre-
therapeutic dosimetry. Indeed, it has been shown that, when
performed at standard nonmyeloablative activities, only
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exceptionally (< 1%) would administration of RIT-Z be con-
traindicated because of excessive absorbed doses to organs at
risk (OARs).4,5 Therefore, for standard treatments, many
countries do not require a pretherapeutic dosimetry study.
In experimental clinical studies, RIT-Z has been also tested
at higher, myeloablative activities, always showing a satis-
factory toxicity profile.6.7 Despite the generally safe profile,
in such trials, a pretherapy dosimetric study is strongly
recommended because of possible, non-negligible organ
toxicities.8
Most dosimetric studies aim therefore at assessing the
safety of RIT, whereas calculation of dose delivered to lesions
has been rare thus far. A few reports on planar two-
dimensional (2D)-conjugated view-based dosimetry of pa-
tients receiving RIT-B failed to show a satisfactory prediction
of tumor response.9,10 When a hybrid method was im-
plemented combining planar imaging with single photon
emission computed tomography (SPECT) and computed
tomography (CT), a closer correlation between dose calcu-
lation and tumor volume reduction was achieved, especially
for small lesions.9,10 These encouraging results were obtained
in previously untreated tumors, in which it might be easier to
find a dose–response relationship. Unfortunately, in patients
with relapsed low-grade or transformed lymphomas, the
efforts to establish a tumor dose–response relationship with a
hybrid three-dimensional (3D) method were unsuccessful;
nevertheless, with the voxel-based analysis, a trend toward
better response with increasing uniformity of dose distribu-
tion was observed.11,12 Nonuniformities of dose distribution
are indeed inherently related to the way of delivering radi-
ation in RIT. If compared to external beam radiotherapy
(EBRT), nonuniformities in RIT are less predictable and, to-
gether with the relatively low administered activity, may
lead to a significant reduction of efficacy. This is especially
the case for RIT-Z, where the administered activity is not
based on dose-limiting toxicity.
One approach to addressing the effect of the heterogeneity
of dose within the target volume is the use of the equivalent
uniform biological effective dose (EU-BED or EUD for short),
defined as the biologically effective dose, which, if delivered
uniformly over the target volume, would yield the same
number of surviving clonogens as the actual, nonuniform
dose distribution.13
Some studies pioneered the systematic application of EUD
in internal dosimetry and indicated the superiority of 3D
biological approaches by demonstrating improved dose–
response correlations in RIT-B.14,15
Besides overcoming some drawbacks of 2D dosimetry,
such as possible overlap between organs and poor differen-
tiation of individual lesions with different biological features
within the same bulk, one of the main advantages of 3D
dosimetry is the possibility to evaluate the dose volume
histograms (DVHs) which, in turn, allow for radiobiological
modeling and for the evaluation of clinically relevant ra-
diobiological parameters (i.e., the EUD).
To our knowledge, voxel-based dosimetry has not been
applied yet to non-Hodgkin lymphoma (NHL) lesions re-
ceiving RIT-Z. Tumor 2D-estimated absorbed dose observed
in clinical trials were in a wide range (5.8–67.1Gy)16 and no
correlation was found with tumor response, even with le-
sions not visualized on 111In-ibritumomab tiuxetan scans
showing good sensitivity to treatment.17,18 A significant
positive correlation between whole-body (WB) dose and
progression-free survival was observed in a subgroup of
patients treated with RIT-Z after the achievement of a re-
sponse (nonmeasurable or low residual tumor burden) to
first-line chemotherapy.19
The present study was carried out to explore the feasibility
of dose distribution analysis within lesions and tumor-
involved organs of patients referred to RIT-Z because of
relapsed/refractory NHL. MATLAB-based software for
voxel-based dosimetry was adopted for this purpose.20
Single-tumor responses as well as organ toxicity are dis-
cussed in view of the dosimetric results.
Methods
Patient enrollment and planar imaging protocol
Seven patients, referred to RIT-Z at the Nuclear Medicine
Department of Sant’Andrea Hospital of Rome between
February 2008 and April 2011 because of recurrent/
refractory NHL, were enrolled in a 3D dosimetry study in
addition to a full planar dosimetry.
The planar dosimetric protocol consisted of several WB
time point scans (10 minutes, 1, 24, 48, 72, 96, and 144 hours)
acquired after the intravenous injection of 111In-Zevalin,
185MBq (5mCi). Before tracer administration, all patients
had received rituximab (Mabthera) 250mg/m2 followed by
a transmission scan using an 111In flood source for attenua-
tion correction. WB images were acquired on a dual-head 5/
8†-thick crystal MEGP-collimated Forte camera (Philips) with
a matrix size of 512 · 512, scan speed 10 cm/min.
To be included in the additional SPECT protocol, patients
were required to show pathological tumor sites at pre-
therapy positron emission tomography (PET/CT), acquired
within 1 month before RIT. After ethical approval, all pa-
tients gave separate informed consent for the planar dosi-
metry as well as for the additional SPECT-based study.
Patients’ characteristics and tumor sites are summarized in
Table 1. The median age was 58 years (range: 32–67 years).
Patients A and B had an untreated relapse of low-grade
(grade 2) follicular lymphoma (FL), while patient C had a
grade 2 FL, which was refractory to the last previous treat-
ment. Four patients had aggressive NHL: patients D, F, and
G had a refractory diffuse large B-cell lymphoma, while
patient E had transformed grade 3b FL. The median number
of prior lines of chemoimmunotherapies was 3 (range: 2–11),
with a median of two prior rituximab-containing regimens
(range: 1–4). Previously, in their treatment course, patients D
and E had received involved-field EBRT and myeloablative
chemotherapy followed by stem cells rescue. Patient G had
received autologous bone marrow transplantation as well.
SPECT imaging protocol
SPECT images (32 steps, 30 seconds/step) encompassing
target lesions were acquired 48, 72, 96, and 144 hours after
the administration of the tracer. In some cases of both upper
and subdiaphragmatic tumor involvement, not covered by
only one SPECT field of view (e.g., patients D, F, and G),
it was not possible to acquire serial images of all lesions
because of patient discomfort. In such cases, SPECTs were
acquired over the biggest or most visible lesions. A matrix
size of 64 · 64, corresponding to a voxel dimension of
VOXEL-BASED DOSIMETRY OF NHL LESIONS 99
9.3 · 9.3 · 9.3mm3, 0.8mL volume), was used. SPECTs were
reconstructed with OSEM algorithm (8 substeps, 12 itera-
tions).20 With the aforementioned acquisition parameters, the
spatial resolution of our SPECT scanner was determined to
be *1.8 cm.
The triple energy window (TEW) technique was used for
scatter correction, as described elsewhere.20,21 TEW algo-
rithm consists of two main 20% energy windows centered at
the 111In photopeaks (171 and 245 keV) and two 6% energy
subwindows on both sides of the main window, centered at
155, 190, and 222 keV, respectively. With the main windows,
the total counts Ctot can be estimated, while the scattered
components Cscat for both photopeaks can be assessed
through the following relations:
Cscat 171¼ C155keVþC190keV
2
 
:
w171
w155=190
Cscat 245¼ C222keV
2
 
:
w245
w222
where C155keV, C190keV, C222keV are the counts in the three
subwindows, which are located, respectively, at the sides of
the main windows and w171, w245, w155/190, w222 are the
width of the main windows and the scatter windows, re-
spectively. The count of primary photons is given by Cprim¼
Ctot (Cscat 171þCscat 245).
For each tumor, attenuation correction was applied by
deriving an attenuation map from images obtained with
the X-ray CT scan. A low-dose CT acquisition protocol for
image attenuation correction was adopted with 120 kV and
70mA. Images were reconstructed at 0.9-cm section thick-
ness with an iterative reconstruction algorithm and a
512 · 512 matrix; the matrix was then scaled to 64· 64 to
match SPECT slices. Linear attenuation coefficients for the
two 111In peaks were determined converting Hunsfield
units by using the bilinear relationships proposed by Brown
et al.22 For each material, the effective attenuation coeffi-
cient was determined as a weighted sum of the 172 and
247 keV attenuation coefficients using weights 0.49 and 0.51,
respectively.
The serial 111In images were aligned using a mutual in-
formation algorithm.20
After corrections, in sequence, for scatter first and for at-
tenuation thereafter, correction for partial volume effect
(PVE) was also performed according to a previously re-
ported method.20
Volume corrections were performed by applying a volume-
dependent intensity threshold on the outlined slices23–25 basing
on individual tumor masses estimated by contouring CT axial
slices with the Varian Eclipse Treatment Planning System for
EBRT. Loss of activity was compensated through the evalua-
tion of volume-dependent recovery coefficients (RCs). RCs
were considered < 1 for the lesions with target volumes larger
than 50mL (See Table 1). Similar corrections have been pre-
viously described26 and applied to patient studies.9,15
Tumor 3D dosimetry
Tumor doseswere estimated bymeans ofMATLAB-based
software, allowing for a direct integration of voxel-based ki-
netic data from SPECT. The original counts were translated
into activity inside the voxels through a phantom-based pro-
cedure that allowed the counts-to-activity calibration factor
(cps/MBq) to be determined. A comprehensive description of
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the phantom procedures can be found elsewhere.20 A homo-
geneous activity distribution was assumed inside each voxel.
To estimate the cumulated activity, individual tumors
were contoured on registered axial SPECTs acquired at dif-
ferent time points by two experienced readers. We decided
not to consider images before 48 hours, since no specific
uptake was generally seen on tumor sites before that time
point, and this might have affected proper tumor contouring.
The same choice was adopted for tumor 2D dosimetry.
Therefore, although estimated doses might be affected by a
small error due to the lack of image sampling before 48
hours, SPECT and planar dose values are comparable.
The cumulated activity concentration in each voxel was
computed for each time point by fitting activity with a mono-
exponential function, and then convolved with voxel S-values
to provide 3D maps of the absorbed dose. The 3D dose dis-
tributionswere then used to deriveDVHs. 3D dose calculations
were performed using the voxel S value approach,27 where
S-values for voxel dimension of 9.3· 9.3· 9.3mm3 were cal-
culated by means of the Monte Carlo N-particle radiation
transport computer code (MCNP, version 4c).20 SPECT cali-
bration procedures, description, and validation of correction
techniques and results of S-value calculations have been ex-
tensively presented elsewhere.20
Tumor response assessment
Three months after RIT-Z, patients underwent either PET/
CT or contrast-enhanced CT (CECT) for response evaluation.
While CECT was performed in different centers according to
the referring hematological institution, pre- and post-therapy
PET/CTwere acquired on the same camera (Philips, Gemini).
Acquisitions (speed: 2.5 cm/min, axial field of view: 18 cm,
50% BED overlap) started 60 minutes after the i.v. injection of
18F-fluorodeoxyglucose (FDG), 3.7MBq/Kg (– 10%). Patients
had been fasting for at least 6 hours and plasma glucose levels
were checked to be £ 140mg/dL before FDG administration.
Response criteria were defined according to the Imaging
Subcommittee of International Harmonization Project in
Lymphoma.28 The presence of residual masses < or ‡ 2 cm in
diameter was considered as a complete response (CR) if the
corresponding FDG uptake was lower compared with the
surrounding background or mediastinal blood pool uptake,
respectively. Conversely, if significant glucose metabolism
was present at the site of residual masses of any size, the
definition of a partial response, stable disease, or progressive
disease (PD) was based on CECTmorphological findings.29 In
such cases, maximum FDG Standardized Uptake Value (SUV
max) measured before and after RIT-Z was reported.
Tumor-involved organs: 3D versus 2D dosimetry
In addition to nodal lesions, 3D dosimetry was also per-
formed using the method described above on the liver and
spleen of patients F and G, to evaluate the dose nonunifor-
mity within these organs. Both patients had stage 4 disease
involving the liver and spleen, which therefore were likely to
show areas of heterogeneous uptake. Although not clearly
identifiable on the pretherapy dosimetric scan, organ in-
volvement was clinically suspected and subsequently con-
firmed by PET/CT.
Voxel-based calculations were compared with standard
2D dosimetry performed by applying the conjugate-view
technique over several time point planar scans according to
MIRD pamphlet 16.30 Scatter and background correction
were performed according to the pseudoextrapolation
number technique30 and Buijs’ method,31 respectively, while
attenuation correction was performed through WB trans-
mission scans using an 111In flood source. Correction for PVE
was not applied to planar dosimetry.
For each time point, tumor/organ uptake was expressed
relative to the body counts obtained 10 minutes after the
injection. Cumulated activities were calculated by fitting the
image-derived time activity to a biesponential function and
analytically integrating the resulting functions. To obtain the
absorbed dose, cumulated activity of organs was then com-
bined with the appropriate dose-conversion S-values re-
trieved from OLINDA software.32 Individual organ masses
were determined by axial CT contouring and input into
OLINDA. The planar dosimetry protocol adopted here has
been previously described.20
The quality of monoexponential and biexponential fit was
assessed by evaluating the coefficient of determination r2 for
each target region. The same approach has been previously
used.20 Single and biexponential fitting techniques were in
good agreement, being in all cases > 0.92. Therefore, the dose
error due to the use of different fitting functions was as-
sumed to be negligible.
Evaluation of nonuniform dose distributions
As reported by O’Donoghue,33 the EUD formalism may be
used to incorporate the biologic effects. By introducing the
radiobiologic parameters a and b, that is, the sensitivity per
unit dose and per unit dose squared, respectively, at the
voxel level, the EUD model converts the heterogeneous D
distribution into an uniform BED that would produce the
same biologic effect as the nonuniform BED distribution.
Therefore, this formalism provides a single value that fully
describes the biologic effect of a nonuniform dose distri-
bution and that can be used to compare different dose
distributions.33
For a given dose distribution, the equivalent uniform bio-
logically effective dose can be calculated as follows:
EUD¼  1
a
ln (S)¼ 1
a
ln
Z1
0
P(w)e awdw
2
4
3
5 Eq: 1
where w represents BED, P(w) the probability density func-
tion, S is the overall surviving fraction for the nonuniform
distribution P(w), e awi is the surviving fraction produced by
a given BED, and a is the radiosensitivity factor. For each
voxel, the BED was calculated as wi¼Di  REi, where Di is the
voxel dose and REi the relative effectiveness evaluated as
reported by Barone et al.34
The relative effectiveness RE depends upon the a/b ratio
and the repair half time for sublethal damage (Tl). In the
present work, the standard values a/b = 10Gy and Tl = 0.5
hours were considered for tumor dosimetry, while a/b =
3Gy and Tl = 3 hours were used both for the liver and
spleen.35
The radiosensitivity a coefficient in Equation 1 was as-
sumed to be 0.35Gy - 1.33 This value is not only limited to RIT
treatments, since a similar a parameter has been previously
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used for systemic radionuclide therapies with various b
emitters36–39 and with radioiodine as well.12 By considering
radiosensitivity a = 0.35Gy - 1, Kalogianni and colleagues as-
sessed the effect of nonuniform activity distributions at a
multicellular scale in terms of DVHs, BED, and EUD for 32P,
90Y, and 131I.39 These authors showed that, for 32P and 90Y,
the loss of therapeutic effect (LTE) is less than for 131I. In fact,
since 32P and 90Y have longer emission ranges, the increased
effect of the cross-fire produces more uniform dose distri-
butions in larger volumes. They also reported that 90Y is
likely to be less effective than 32P and 131I, because of its
shorter physical half-life resulting in lower mean BED values.
The probability density function P(w) corresponds to the
differential BED distribution, or differential BED volume
histograms (BVHs), normalized so that the area under the
curve is 1, and is retrieved by differential DVH (See Fig. 2).
To quantify dose uniformity both in tumor regions and
OARs, for each target area, a heterogeneity index (HI) was
defined as the ratio of the dose delivered to 5% and 95% of
the target volume. A larger HI indicates greater dose het-
erogeneity inside the lesion.40 For each lesion, the LTE for a
given dose distribution was calculated as the difference be-
tween the mean BED and the EUD.33
Results
Dosimetry: single tumors
Differential DVHs, normalized so that the area under the
curve is 1, are shown in Figure 1. BEDs of low-grade lesions
were in the range 2.62–9.68Gy (median: 3.75Gy), while they
were in the range 2.86–4.33Gy (median: 4.18Gy) in high-
grade lymphomas.
As expected, EUDs were systematically lower than BEDs,
being in the range 2.57–9.04Gy (median: 3.66Gy) and 2.82–
4.17 (median: 3.9Gy) for low- and high-grade lymphomas,
respectively. The complete list of values is reported in Table
2, together with HI, LTE, and surviving fractions (S) fol-
lowing uniform irradiation of a cell population S = e - aEUD.
As a general rule, as the distribution becomes less uniform,
the EUD decreases and—as reported by O’Donoghue33—
the higher the absorbed dose, the higher the effect of dose
nonhomogeneity on therapeutic effect (see Table 2). Indeed,
our data confirm that the absolute LTE is greater for higher
BED values (Fig. 3).33
Dosimetry: organs
Table 3 shows 2D and 3D dose calculations for NHL in-
volved organs of patients F and G, while the corresponding
DVHs are depicted in Figure 4. Since the concept of thera-
peutic effectiveness is related only to tumor, LTE and S for
tumor-involved organs have not been reported in Table 3.
Liver BED of patient G was higher compared with patient F
(8.46 vs. 4.15Gy, respectively). Heterogeneity was higher
(HI = 1.9 vs. 1.6) in the liver of patient F, showing multiple
single metastases (See Fig. 5), than in the liver of patient G,
whose liver involvement was diffuse.
FIG. 1. Differential dose volume histograms (DVHs) for
lesions, normalized so that the area under the curve is 1.
Dose distribution, reported as a differential DVH, provides
an accurate assessment of homogeneity in the volume of
interest. Each DVH represents the tumor volume receiving a
dose given by the bin. Bin doses are shown on the horizontal
axis (1Gy-bin size), whereas structure volumes—reported as
a fraction of the whole volume—are on the vertical axis.
Color images available online at www.liebertpub.com/cbr
Table 2. Results of Tumor Dosimetry
LTE
Lesion Mass (g) BED (Gy) EUD (Gy) S HI (Gy) (%) Outcome
1 107 9.26 8.63 0.05 1.91 0.63 - 6.80 CR
2 80 3.75 3.66 0.28 3.58 0.09 - 2.40 CR
3 125 8.39 8.03 0.06 1.77 0.36 - 4.29 CR
4 60 3.44 3.31 0.31 4.43 0.13 - 3.78 CR
5 11 9.68 9.04 0.04 1.97 0.64 - 6.61 CR
6 30 2.75 2.69 0.39 3.57 0.06 - 2.18 PD
7 17 2.62 2.57 0.41 3.39 0.05 - 1.91 PD
8 378 4.20 3.96 0.25 3.07 0.24 - 5.71 PD
9 38 4.33 4.17 0.23 4.13 0.16 - 3.70 SD
10 108 4.16 3.85 0.26 5.91 0.31 - 7.45 Unknown
11 120 2.86 2.82 0.37 1.55 0.04 - 1.40 SD
BED, biological effective doses; EUD, equivalent uniform biological effective dose; HI, heterogeneity index; LTE, loss of therapeutic effect;
CR, complete response; PD, progressive disease; SD, stable disease.
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The two spleens received similar doses (4.14 vs. 4.66Gy).
Again, the organ with more focal pattern of involvement
(patient G, See Fig. 6) showed higher HI (HI = 1.42 vs. 1.75)
than the liver whose tumor involvement was fairly diffuse
(patient F, see Fig. 5). In all the 4 organs analyzed, 2D do-
simetry gave lower doses than 3D dosimetry (See Table 3).
Response assessment
Nine (number 1–7, 9, 11) out of 11 lesions were classified
by combining information from post-therapy PET/CT and
CECT. Lesion 8 (patient D) was restaged on the basis of
physical examination and CT only, before the patient was
referred to subsequent salvage therapy. Both patients F and
G died several months after RIT-Z. While the response of
lesion 11 (patient G) could be evaluated by post-therapy
PET/CT (Fig. 6), the death of patient F occurred before
response of lesion number 10 and post-therapy status of
parenchymal disease could be classified.
Five low-grade lymphoma lesions (number 1–5) showed a
CR; lesions number 6, 7, and 8 (patients C and D) progressed
after RIT-Z. Lesions number 9 and 11 (patients E and G) were
stable but, due to the appearance of newly involved sites,
those patients were considered globally progressive. Pre-
and post-therapy SUV max values of lesion number 9 were
11.1 and 5, respectively (SUV reduction = 55%), while they
were 25.7 and 3.8 in lesion number 11 (SUV reduction = 96%)
(Fig. 6). Lesion 10 could not be classified in terms of response
because of the early death of patient F. Patient F died of a
pulmonary edema during bone marrow aplasia, with febrile
neutropenia and severe diarrhea; death occurred 2 months
after RIT-Z and was attributed to hematological toxicity, no
autopsy was performed. Patient G expired 3.5 months after
RIT-Z. A direct cause of death was pulmonary edema; how-
ever, concomitant hepatic iatrogenic necrosis and NHL liver
involvement were diagnosed at autopsy. The observed liver
toxicity was not predictable based on the estimated absorbed
dose (Table 3). Both the liver and spleen of patient G showed a
dramatic volumetric increase from pre- to post-therapy PET/
CT (2230 vs. 3420g for liver, 415 vs. 1184g for spleen); how-
ever, while on post-therapy PET/CT, the spleen was clearly
abnormal, liver glucose uptake was more homogeneous than
before, without signs of disease progression (Fig. 6).
FIG. 3. Absolute loss of therapeutic effect (LTE) versus BED
in lesions. LTE is worse for larger mean BED values.
Table 3. Dose Estimations for Liver and Spleen
of Patients F and G
Organs Patients
Mass
(g)
2D dose
(Gy)
3D dose
(Gy)
BED
(Gy) HI
EUD
(Gy)
Liver
F 2130 2.40 4.10 4.15 1.90 4.0
G 2230 5.50 8.30 8.46 1.60 8.13
Spleen
F 1337 2.40 4.10 4.14 1.42 4.09
G 415 3.30 4.60 4.66 1.75 4.50
FIG. 4. Differential DVHs for organs at risk.
FIG. 2. Lesion 1: differential DVH (dotted line) and bio-
logical effective doses (BED) volume histogram P(w) nor-
malized such that the area under the curve is 1 (BED volume
histogram [BVH], black solid line). Average absorbed dose
and BED are also reported. The solid line outlining the dia-
gonals represents the resulting distribution of survival
probability calculated for tumor radiosensitivity parameter
of 0.35Gy - 1. The smaller, dashed area represents the overall
surviving fraction for the nonuniform distribution P(w), cal-
culated by the Laplace transform of the BVH (equation in the
graph). EUD, equivalent uniform biological effective dose.
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Discussion
To our knowledge, this is the first report analyzing dose-
volume distributions and applying the EUD concept to NHL
lesions receiving RIT-Z.41 We are aware that the population
under study and the incomplete sampling of tumor lesions
would not allow a robust dose–response analysis on patient
basis, which therefore was not attempted. Rather, our aim
was to show the feasibility and discuss some implications
of such approach, as we believe that the application of ra-
diobiologic modeling to patient-specific 3D imaging may
provide new insights into tumor and organ dosimetry.42
Our results confirm that dose nonuniformities in RIT are
quite large, resulting in higher HI values compared to
FIG. 5. Pretherapy FDG
PET/CT of patient F. A
pattern of focal tumor
involvement is shown, with
multiple hepatic lesions
(coronal and axial slices).
Color images available
online at www.liebertpub
.com/cbr
FIG. 6. Pre- and post-therapy imaging of patient G. (A) pretherapy 111In-single photon emission computed tomography
(SPECT); (B, C) pre- and post-therapy PET/CT. Although 111In-SPECT showed poor uptake (A, coronal slice) in the medi-
astinal lesion, maximum FDG Standardized Uptake Value (SUV max) decreased from 25.66 before (B) to 3.8 after therapy (C).
C depicts the good response of abdominal as well as supraclavicular nodes, whereas hilar nodes progressed bilaterally.
Diffuse hepatic involvement was present before therapy (B). After RIT-Z, while liver uptake was almost homogeneous, the
spleen showed clear disease progression (C).
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conventional EBRT. Moreover, the intratumoral distribution
of 90Y-ibritumomab-tiuxetan varies widely among tumors
and is apparently not dependent on tumor mass. As shown
by the comparisons between lesions 1 and 10 and between
lesions 1 and 5, respectively, HI of lesions with similar mass
can be very different, and HI of lesions with very different
mass can be similar (See Table 2). As previously described,
LTE is lower for lesions receiving low average doses.33
However, the contribution of predicted LTE and S on tumor
control will hopefully be clarified in larger series of patients.
Interestingly, despite 28% and 31% estimated surviving
tumor cells in lesions number 2 and 4, respectively, both
responded completely to treatment, and remain in CR 10
months after RIT-Z.
Consistent withmost previous reports inNHL, the response
observed in single lesions was apparently not dependent on
the calculated dose, and varied according to tumor aggres-
siveness. Of note, probably because of the small patient sample
size, the tumor dose range observed was smaller than previ-
ously reported,16 and all lesions received doses that would
have been considered suboptimal according to the current
standard of EBRT (30–36Gy). The need for 30–36Gy has been
questioned in case of both indolent and aggressive lympho-
mas, although the evidence supporting the efficacy of low ra-
diation doses is stronger for indolent than for aggressive
lymphomas.43,44 It is well known that the efficacy of RIT-Z is
low in patients with aggressive lymphomas, especially those
with previous exposure to rituximab.45 Unfortunately, in case
of progression after optimized rituximab-including treatments,
the efficacy of RIT-Z is reduced in patients with indolent
lymphomas as well.46,47 A possible acquired resistance to im-
munotherapy, together with the low radiation doses, might
explain the treatment failure of patient C, whereas the tumors
of patients A and B were more sensitive, as they had already
achieved CRs after prior optimized treatments. A compre-
hensive understanding of all the variables affecting tumor
sensitivity is a long way away; even more distant is a tailored
treatment based on tumor dose predictions. However, opti-
mization of doses in RIT would be welcome, so the technique
developed here warrants further investigation.
A method for 3D dose calculation could be successfully
applied to organs with disease involvement where a hetero-
geneous dose distribution ismore likely than in healthy organs.
Thus, we conducted a separate analysis on the liver and spleen
of two patients (F and G) with extensive tumor involvement,
comparing voxel-based 3D calculations with 2D dosimetry.
Although most studies indicate that 3D doses are generally
lower than those obtained with planar dosimetry,48 the oppo-
site was found in our series. Although this observation might
be serendipitous, we believe that it could be potentially related
to the massive organ tumor involvement. Interestingly, when
the same methodology and the same corrections were applied
to organs without tumor involvement, 3D determined ab-
sorbed doses turned out to be generally lower than 2D.20
Both patients F and G had PD after several courses of che-
moimmunotherapy; patient G had already received high-dose
chemotherapy with stem cell rescue and had prior history of
drug abuse (cannabinoids and cocaine) since the age of 14.
Before RIT, liver function tests and viral serology (HBV, HCV,
HIV) were unremarkable in both patients. The liver toxicity of
patient G was not curable and significantly worsened his
prognosis. The reason for such toxicity was not entirely clear,
since dose estimates—with either of the two methods—were
largely within tolerable limits. Nonetheless, PET images ob-
tained before RIT showed significantly different patterns of
liver involvement between these two patients: the liver of
patient F showed up to 13 single well-defined lesions (Fig. 5),
while the liver of patient G exhibited a diffuse metastatic
spread, without clearly defined foci of FDG uptake (Fig. 6).
Therefore, it may be possible that, due to the apparently more
diffuse tumor infiltrate, the liver of patient G was more com-
promised than the liver of patient F. Unfortunately, we did not
have a direct comparison of liver toxicity between patients F
and G; we only could observe that, unlike patient G, patient F
conserved unremarkable liver function indices until death,
which occurred 60 days after RIT-Z.
To our knowledge, there is no literature addressing dif-
ferent radiosensitivities for organs with tumor involvement.
In fact, in EBRT, metastatic organs conserve the a/b para-
meters of healthy organs. In our opinion, this would be an
interesting and almost unexplored field of research.
Finally, we would like to discuss some methodological
differences between the present work and previous voxel-
based dosimetric studies.
In the present article, 3D dose calculations were per-
formed using the voxel S value method.27 It is worth noting
that other algorithms, such as the dose point kernel convo-
lution49,50 and the direct Monte Carlo radiation transport
technique27 are available and often implemented in clinical
practice. However, the voxel S value and the dose point–
kernel algorithms are generally considered to be good com-
promises between simplified model-based calculations and
more resource-intensive approaches based on Monte Carlo
radiation transport.49 In addition, they are likely to provide
similar results.27,49–51 Recently, a dose calculation algorithm
that assumes that kinetic energy is deposited in the same
voxel where particles are emitted has been described.52 In-
terestingly, this latter study demonstrates that dosimetry
using explicit Monte Carlo calculations is not always war-
ranted, since the limited spatial resolution of the SPECT
imaging system is in the same order of magnitude as com-
pared to the b particle ranges.52
Our choice of a 9.3-mm3 voxel yielded a high self-dose
within the source voxel, while S values of adjacent voxels
decrease rapidly.20 As a consequence, the convolution of a
high S value in the centroid voxel would produce approxi-
mately the same result than considering that all kinetic en-
ergy is deposited within the voxel where the decay has
occurred (local absorption of dose).
We acknowledge that, with such voxel size, no conclusions
about heterogeneous activity distributions below 0.8mL (i.e.,
the voxel volume) can be drawn. The impact of a heteroge-
neous submillimetric dose distribution is hardly quantifiable
and goes beyond the scope of the present study. However, as
a general rule of thumb, the spatial scale of heterogeneity
depends on the physical properties of radiation. If there are a
large number of b particle tracks (as is the case of tumor
areas, which show regions of high uptake), it is likely that the
constituents of individual tracks occupy overlapping physi-
cal volumes, therefore approaching a homogeneous distri-
bution.53 This may be particularly true when the b particle
range is larger than—or approximately the same size as—the
voxel dimension. This is the case of the present study, where
the cross-fire deriving from 90Y electrons (maximal range
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*11mm) is likely to reduce intra-voxel heterogeneities.
Hence, in our opinion, though large, a 9.3-mm cubic voxel is
not an obstacle for tumor contouring and is not likely to affect
dose calculations since, to a first approximation, intravoxel
heterogeneity may be assumed negligible.
As most recent guidelines28 recommend, we included
PET/CT in the response evaluation to better account for
tumor metabolism. Changes in glucose uptake are indeed
more closely related to cell killing/regrowth rates than
changes in tumor volume. The combined utilization of mor-
phological and metabolic criteria for response assessment
represents one of the major differences between the present
study and the previous reports on Bexxar.9–12,14,15 In the ab-
sence of a hybrid SPECT/CT scanner, we decided to contour
tumors on SPECT images rather than on CT axial slices for
activity quantification. Our decision was based on the as-
sumption that tumor volumes calculated on SPECT images
might better correspond to the actual tumor than noncontrast
enhanced, low-dose CT images. Volumes derived by CT were
used for partial-volume corrections and activity recovery,
performed through the application of volume thresholds and
activity RCs, respectively. After proper corrections, SPECT-
based tumor volumes were in good agreement with those
assessed fromCT, with amaximum overestimation of 13% for
the smallest lesion. Dedicated phantom studies, assessing the
agreement between nominal and SPECT-evaluated volumes,
were presented elsewhere.20
Also, differently from previous reports on RIT-B dosi-
metry,14,15 we did not consider the potential contribution of
tumor shrinkage and unlabelled antibody during therapy on
dose calculations. Although indolent NHLs are potentially
sensitive to rituximab alone even after RIT-Z,47 tumor
shrinkage during pretherapeutic imaging or soon after the
administration of the therapeutic activity has not yet been
recorded in RIT-Z. Interestingly, with RIT-B, more than 50%
volume reduction was observed after the administration of
unlabelled tositumomab in previously untreated lesions,10
while in relapsed patients the contribution of cold tositu-
momab was less, but still significant.11,14,15 Systematic use of
SPECT/CT in the pretherapeutic dosimetry of RIT-Z should
be able to address the issue of any possible contribution of
unlabelled rituximab.
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